1994 Volume 42 Issue Supplement4 Pages 342-349
Fundamental and clinical evaluation of biapenem (BIPM), a new carbapenem antibiotic, was studied, yielding the following results.
1) Antibacterial activities
Antibacterial activities of BIPM were studied against clinical isolates such as methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus.
The MIC90 of BIPM was 0.1μg/ml for MSSA, 25μg/ml for MRSA, 0.1μg/ml for E. coli, 0.1μg/ml forC. freundii, 0.39μg/ml for K. pneumoniae, 3.13μg/ml for P. mirabilis, 3.13μg/ml for P. aeruginosa, 6.25μg/ml for S. marcescens and 0.2μg/ml for A. calcoaceticus.
2) Absorption and excretion
When BIPM was administered to 3 patients with various degrees of renal impairment by intravenous drip infusion, the serum levels reached 20.8μg/ml at the time when the infusion was over and a-half life was 2.14 hours.
Urinary recovery rate in the first 12 hours was about 36.3% after drip infusion of 300mg of BIPM. In hemodialystics-patients, the half life was shortened from 4.13 hours to 1.04 hours.
3) Clinical results
14 patients with respiratory tract infection were given 150 to 300mg of BIPM twice a day by intravenous drip infusion. The clinical response was excellent in 1 case, good in 12 cases and unevaluable in 1 case.
No side effect and abnormal laboratory findings were observed.
